Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
  1. Home
  2. Search

Refine search

Refine search

Access:
Content type:
Publication date:
Apply   From and To filters
Subject: Show more
Journals Show more
Publishers: Show more
Societies Show more
Series: Show more
Collections: Show more

Actions for selected content:

Select all | Deselect all
  • View selected items
  • Export citations
  • Download PDF (zip)
  • Save to Kindle
  • Save to Dropbox
  • Save to Google Drive

Save Search

You can save your searches here and later view and run them again in "My saved searches".

Please provide a title, maximum of 40 characters.
Cancel
×

1 results

  • 14 - Pharmacogenetics of anxiolytic drugs and the GABA–benzodiazepine receptor complex

  • from Part V - Specific psychotropic drugs and disorders
  • Edited by Bernard Lerer, Hadassah-Hebrew Medical Center, Jerusalem
  • Book:
    Pharmacogenetics of Psychotropic Drugs
    Published online:
    20 August 2009
    Print publication:
    29 August 2002, pp 300-319

  • Summary

    The benzodiazepines (BDZ) have proven to be both effective and controversial in the treatment of anxiety. New insights into the genetics of the BD2 receptor system may lead to the development of new drugs that act on the γ-aminobutyric acid (GABA) receptor complex and are devoid of the problems associated with the classical BDZs. This pharmacotherapeutic approach has gathered impetus following the discovery of the various subunits of the GABA receptor, which play an important role in the regulation of anxiety and the actions of anxiolytics, and which demonstrate differential brain expression. This chapter discusses the above with reference to recent evidence from animal and human studies, as well as the implications for future anxiolytic treatment strategies. It focuses on the development of the GABA-BDZ receptor field of research. Unlike the BDZ site, the modulation of the GABA receptor by neurosteroids requires the presence of a β-subunit.